1. To identify patients with NAFLD at risk of advanced liver disease.
2. To understand the application of available medications for associated comorbidities that can benefit patients with NASH.
3. To be aware of the drugs nearing FDA approval for NASH
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation